Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact
information

Inflammation

Inflammatory disease

Inflammatory monocytes

Studies in mice suggest negatively charged nanoparticles could help treat inflammatory diseases by preventing migration of inflammatory monocytes. In a mouse model of West Nile virus encephalitis, negatively charged nanoparticles decreased seizures and levels of inflammatory cytokines and chemokines and increased survival compared with neutral nanoparticles or vehicle. In mouse models of peritoneal inflammation, multiple sclerosis (MS), myocardial infarction (MI) or ischemia/reperfusion injury, the negatively charged nanoparticles decreased both migration of inflammatory monocytes to sites of inflammation and disease symptoms compared with neutral nanoparticles or vehicle. Ongoing studies at Cour Pharmaceutical Development Co. Inc. include toxicity testing to support clinical trials in MI (see Negative nanoparticles, page 6).

SciBX 7(5); doi:10.1038/scibx.2014.148
Published online Feb. 6, 2014

Patented by Getts Consulting and Project Management; licensed to Cour Pharmaceutical

Getts, D.R. et al. Sci. Transl. Med.; published online Jan. 15, 2014;
doi:10.1126/scitranslmed.3007563
Contact: Nicholas J.C. King, Sydney Medical School at The University of Sydney, Sydney, New South Wales, Australia
e-mail:
nickk@pathology.usyd.edu.au

Contact: Stephen D. Miller, Northwestern University Feinberg School of Medicine, Elmhurst, Ill.
e-mail:
s-d-miller@northwestern.edu

Contact: Daniel R. Getts, same affiliation as above
e-mail:
d-getts@northwestern.edu